カテゴリー： Transparency Market Research, 世界, 医療/バイオ

世界の色素沈着治療市場2022年ｰ2031年：治療タイプ別（化粧品、レーザー治療、ケミカルピーリング、マイクロダーマブレーション、光線治療、その他）

◆英語タイトル：Hyperpigmentation Disorder Treatment Market (Treatment Type: Cosmeceuticals, Laser Therapy, Chemical Peels, Microdermabrasion, Phototherapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Transparency Market Researchが発行した調査報告書（TMR23JA065）◆商品コード：TMR23JA065
◆発行会社（リサーチ会社）：Transparency Market Research
◆発行日：2022年11月1日
◆ページ数：113
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社は、世界の色素沈着治療市場について調査し、序論、仮定・調査手法、市場概要、主要インサイト、治療タイプ別（化粧品、レーザー治療、ケミカルピーリング、マイクロダーマブレーション、その他）分析、疾患別（肝斑、炎症後色素沈着、日光性黒子、その他）分析、エンドユーザー別（病院、エステティックサロン＆皮膚科クリニック、その他）分析、地域別（北米、中南米、ヨーロッパ、アジア太平洋、中東/アフリカ）分析、競争状況、企業情報などの内容を掲載しています。なお、当書に掲載されている企業情報には、Aerolase Corporation、Candela Corporation、Cynosure、Galderma S.A.、iSCLINICAL、ISDIN、L'Oréal (SkinCeuticals, Skinbetterscience & La Roche-Posay)、LumenisBe Ltd.、Mesoestetics、Obagi Cosmeceuticals LLCなどが含まれています。
・序論
・仮定・調査手法
・市場概要
・主要インサイト

・世界の色素沈着治療市場規模：治療タイプ別
- 化粧品治療の市場規模
- レーザー治療の市場規模
- ケミカルピーリング治療の市場規模
- マイクロダーマブレーション治療の市場規模
- その他治療タイプの市場規模

・世界の色素沈着治療市場規模：疾患別
- 肝斑の市場規模
- 炎症後色素沈着の市場規模
- 日光性黒子の市場規模
- その他疾患の市場規模

・世界の色素沈着治療市場規模：エンドユーザー別
- 病院における市場規模
- エステティックサロン＆皮膚科クリニックにおける市場規模
- その他エンドユーザーにおける市場規模

・世界の色素沈着治療市場規模：地域別
- 北米の色素沈着治療市場規模
- ヨーロッパの色素沈着治療市場規模
- アジア太平洋の色素沈着治療市場規模
- 中東/アフリカの色素沈着治療市場規模

・競争状況
・企業情報

Hyperpigmentation Disorder Treatment Market – Scope of Report
TMR’s report on the global hyperpigmentation disorder treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global hyperpigmentation disorder treatment market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hyperpigmentation disorder treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the hyperpigmentation disorder treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hyperpigmentation disorder treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global hyperpigmentation disorder treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hyperpigmentation disorder treatment market.

The report delves into the competitive landscape of the global hyperpigmentation disorder treatment market. Key players operating in the global hyperpigmentation disorder treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global hyperpigmentation disorder treatment market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market hyperpigmentation disorder treatment.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

❖ レポートの目次 ❖

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hyperpigmentation Disorder Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hyperpigmentation Disorder Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Market Trends
5.2. Merger and Acquisition
5.3. Strategies of Top Five Players Operating in the Market
5.4. Incidence of Orthopedic Disorder, by Key Countries
5.5. Regulatory and Reimbursement Scenario, by Key Countries
6. Global Hyperpigmentation Disorder Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Market Value Forecast, by Treatment Type, 2017–2031
6.2.1. Cosmeceuticals
6.2.2. Laser Therapy
6.2.3. Chemical Peels
6.2.4. Microdermabrasion
6.2.5. Phototherapy
6.2.6. Others
6.3. Market Attractiveness, by Treatment Type
7. Global Hyperpigmentation Disorder Treatment Market Analysis and Forecast, by Disease Indication
7.1. Introduction & Definition
7.2. Market Value Forecast, by Disease Indication, 2017–2031
7.2.1. Melasma
7.2.2. Post-inflammatory Hyperpigmentation
7.2.3. Solar Lentigines
7.2.4. Others
7.3. Market Attractiveness Analysis, by Disease Indication
8. Global Hyperpigmentation Disorder Treatment Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Market Value Forecast, by End-user, 2017–2031
8.2.1. Hospitals
8.2.2. Esthetic Clinics & Dermatology Centers
8.2.3. Others
8.3. Market Attractiveness Analysis, by End-user
9. Global Hyperpigmentation Disorder Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Hyperpigmentation Disorder Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2031
10.2.1. Cosmeceuticals
10.2.2. Laser Therapy
10.2.3. Chemical Peels
10.2.4. Microdermabrasion
10.2.5. Phototherapy
10.2.6. Others
10.3. Market Value Forecast, by Disease Indication, 2017–2031
10.3.1. Melasma
10.3.2. Post-inflammatory Hyperpigmentation
10.3.3. Solar Lentigines
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Esthetic Clinics & Dermatology Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Disease Indication
10.6.3. By End-user
10.6.4. By Country
11. Europe Hyperpigmentation Disorder Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2031
11.2.1. Cosmeceuticals
11.2.2. Laser Therapy
11.2.3. Chemical Peels
11.2.4. Microdermabrasion
11.2.5. Phototherapy
11.2.6. Others
11.3. Market Value Forecast, by Disease Indication, 2017–2031
11.3.1. Melasma
11.3.2. Post-inflammatory Hyperpigmentation
11.3.3. Solar Lentigines
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Esthetic Clinics & Dermatology Centers
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Disease Indication
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Hyperpigmentation Disorder Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Cosmeceuticals
12.2.2. Laser Therapy
12.2.3. Chemical Peels
12.2.4. Microdermabrasion
12.2.5. Phototherapy
12.2.6. Others
12.3. Market Value Forecast, by Disease Indication, 2017–2031
12.3.1. Melasma
12.3.2. Post-inflammatory Hyperpigmentation
12.3.3. Solar Lentigines
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Esthetic Clinics & Dermatology Centers
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Disease Indication
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Hyperpigmentation Disorder Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2031
13.2.1. Cosmeceuticals
13.2.2. Laser Therapy
13.2.3. Chemical Peels
13.2.4. Microdermabrasion
13.2.5. Phototherapy
13.2.6. Others
13.3. Market Value Forecast, by Disease Indication, 2017–2031
13.3.1. Melasma
13.3.2. Post-inflammatory Hyperpigmentation
13.3.3. Solar Lentigines
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Esthetic Clinics & Dermatology Centers
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Disease Indication
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Hyperpigmentation Disorder Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2017–2031
14.2.1. Cosmeceuticals
14.2.2. Laser Therapy
14.2.3. Chemical Peels
14.2.4. Microdermabrasion
14.2.5. Phototherapy
14.2.6. Others
14.3. Market Value Forecast, by Disease Indication, 2017–2031
14.3.1. Melasma
14.3.2. Post-inflammatory Hyperpigmentation
14.3.3. Solar Lentigines
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Esthetic Clinics & Dermatology Centers
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment Type
14.6.2. By Disease Indication
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competitive Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. Aerolase Corporation
15.3.1.1. Company Overview
15.3.1.2. Treatment Type Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Candela Corporation
15.3.2.1. Company Overview
15.3.2.2. Treatment Type Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Cynosure
15.3.3.1. Company Overview
15.3.3.2. Treatment Type Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.4. Galderma S.A.
15.3.4.1. Company Overview
15.3.4.2. Treatment Type Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. iSCLINICAL
15.3.5.1. Company Overview
15.3.5.2. Treatment Type Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. ISDIN
15.3.6.1. Company Overview
15.3.6.2. Treatment Type Portfolio
15.3.6.3. SWOT Analysis
15.3.7. L’Oréal (SkinCeuticals, Skinbetterscience & La Roche-Posay)
15.3.7.1. Company Overview
15.3.7.2. Treatment Type Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Lumenis Be Ltd.
15.3.8.1. Company Overview
15.3.8.2. Treatment Type Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. Mesoestetics
15.3.9.1. Company Overview
15.3.9.2. Treatment Type Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Obagi Cosmeceuticals LLC
15.3.10.1. Company Overview
15.3.10.2. Treatment Type Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. PCA Skin
15.3.11.1. Company Overview
15.3.11.2. Treatment Type Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Scientis
15.3.12.1. Company Overview
15.3.12.2. Treatment Type Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Senté Labs
15.3.13.1. Company Overview
15.3.13.2. Treatment Type Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. SkinMedica (AbbVie)
15.3.14.1. Company Overview
15.3.14.2. Treatment Type Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
15.3.15. ZO Skin Health, Inc.
15.3.15.1. Company Overview
15.3.15.2. Treatment Type Portfolio
15.3.15.3. SWOT Analysis
15.3.15.4. Financial Overview
15.3.15.5. Strategic Overview



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界の色素沈着治療市場2022年ｰ2031年：治療タイプ別（化粧品、レーザー治療、ケミカルピーリング、マイクロダーマブレーション、光線治療、その他）(Hyperpigmentation Disorder Treatment Market (Treatment Type: Cosmeceuticals, Laser Therapy, Chemical Peels, Microdermabrasion, Phototherapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 世界の色素沈着症治療市場2023-2031：治療法別（外用薬、レーザー治療、ケミカルピーリング、マイクロダーマブレーション、光線療法、その他）
  • 小細胞肺がん（SCLC）治療薬の世界市場2023～2031：治療タイプ別、投与経路別

    • ◆H&Iグローバルリサーチのお客様（例）◆